Evacetrapib
- Generic Name
- Evacetrapib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H36F6N6O2
- CAS Number
- 1186486-62-3
- Unique Ingredient Identifier
- 51XWV9K850
- Background
Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Different Particle Sizes of Evacetrapib in Healthy Participants
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 95
- Registration Number
- NCT02497391
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT02365558
- Locations
- 🇺🇸
Covance Madison, Madison, Wisconsin, United States
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT02260635
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 149
- Registration Number
- NCT02260648
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 366
- Registration Number
- NCT02227784
- Locations
- 🇺🇸
Alan Graff, MD, PA, Fort Lauderdale, Florida, United States
🇺🇸Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
A Study of Evacetrapib in Healthy Japanese Participants
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02226653
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study of Evacetrapib in Participants With Abnormal Cholesterol
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 101
- Registration Number
- NCT02168803
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸Covance Clinical Research Inc, Madison, Wisconsin, United States
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02161731
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT02156492
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China
A Study of Evacetrapib in Japanese and Non-Japanese Participants
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01958489
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.